Summary. Epidermal growth factor (EGF) and its receptors (HER/ErbB family) are essential regulators of cellular proliferation, survival, angiogenesis, and differentiation. Their dysregulation is central to the pathogenesis of various cancers and viral infections. This review analyzes the structure, ligand-binding, and dimerization of HER-1, HER-2, HER-3, and HER-4, and their downstream signaling pathways such as MAPK, PI3K, and PKC. HER-2 is emphasized as a pivotal oncogenic driver in breast, ovarian, gastric, and bladder carcinomas, where targeted therapeutics including trastuzumab, lapatinib, neratinib, and afatinib are clinically used. Resistance mechanisms and the role of heat shock protein inhibitors (e.g., ganetespib) in enhancing therapy are discussed. Additionally, EGFR-mediated pathways are shown to facilitate entry of viruses like hepatitis C and B, by exploiting host receptor complexes involving CD81 and claudin-1. The review further explores natural polyphenols (delphinidin, quercetin, EGCG) as novel EGFR/ErbB2 tyrosine kinase inhibitors with anticancer and antiviral potential. These findings underscore the multifaceted role of the EGFR/ErbB system as a target for innovative therapeutic strategies in oncology and virology. Keywords: epidermal growth factor, HER/ErbB receptors, tyrosine kinase inhibitors, targeted therapy, breast cancer, hepatitis C virus, flavonoids, EGFR inhibitors, virus entry.